INSM:NGS-Insmed Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 63.92

Change

+2.29 (+3.72)%

Market Cap

USD 0.88B

Volume

3.30M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insmed Inc is a biopharmaceutical company. The Company is developing ARIKAYCE for inhalation (LAI), for patients with nontuberculous mycobacteria lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.10 (+0.88%)

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

+5.28 (+0.51%)

USD 115.08B
MRNA Moderna Inc

+1.13 (+0.85%)

USD 51.07B
BNTX BioNTech SE

-0.39 (-0.45%)

USD 24.18B
ARGX argenx NV ADR

+9.91 (+2.62%)

USD 23.18B
ALNY Alnylam Pharmaceuticals Inc

+3.54 (+2.30%)

USD 19.48B
GMAB Genmab AS

+0.08 (+0.31%)

USD 18.17B
BGNE BeiGene Ltd

+0.84 (+0.54%)

USD 17.50B
RPRX Royalty Pharma Plc

+0.37 (+1.41%)

USD 15.90B
BMRN Biomarin Pharmaceutical Inc

+0.56 (+0.67%)

USD 15.32B

ETFs Containing INSM

PINK Simplify Exchange Traded .. 5.48 % 0.00 %

+0.18 (+0.60%)

USD 0.12B
BBP Virtus LifeSci Biotech Pr.. 4.27 % 0.79 %

+0.03 (+0.60%)

USD 0.02B
XBI SPDR® S&P Biotech ETF 2.31 % 0.35 %

+0.19 (+0.60%)

USD 7.07B
CURE:AU ETFS S&P Biotech ETF 2.25 % 0.00 %

+0.34 (+0.60%)

USD 0.04B
BTEC Principal Healthcare Inno.. 1.85 % 0.42 %

+0.04 (+0.60%)

USD 0.02B
LABU Direxion Daily S&P Biotec.. 1.57 % 1.14 %

+0.82 (+0.60%)

USD 1.01B
IWO iShares Russell 2000 Grow.. 0.76 % 0.24 %

-1.80 (0.60%)

USD 10.83B
BBSC JPMorgan BetaBuilders U.S.. 0.63 % 0.00 %

-0.28 (0.60%)

USD 0.47B
VTWG Vanguard Russell 2000 Gro.. 0.60 % 0.20 %

-1.20 (0.60%)

USD 0.88B
IWM iShares Russell 2000 ETF 0.38 % 0.19 %

-0.85 (0.60%)

USD 59.22B
UWM ProShares Ultra Russell20.. 0.27 % 0.95 %

-0.33 (0.60%)

USD 0.19B
URTY ProShares UltraPro Russel.. 0.21 % 0.95 %

-0.66 (0.60%)

USD 0.35B
HDG ProShares Hedge Replicati.. 0.06 % 0.95 %

+0.03 (+0.60%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 106.26% 92% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.26% 92% A 96% N/A
Trailing 12 Months  
Capital Gain 219.60% 98% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 219.60% 98% N/A 98% N/A
Trailing 5 Years  
Capital Gain 168.57% 88% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 168.57% 88% B+ 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 35.94% 82% B 87% B+
Dividend Return 35.94% 82% B 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 357.95% 10% F 5% F
Risk Adjusted Return 10.04% 68% D+ 49% F
Market Capitalization 0.88B 98% N/A 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 25.45 6% 4%
Price / Cash Flow Ratio -17.29 89% 86%
Price/Free Cash Flow Ratio -6.78 79% 80%
Management Effectiveness  
Return on Equity -1,453.41% 5% 2%
Return on Invested Capital -69.94% 43% 18%
Return on Assets -31.79% 48% 17%
Debt to Equity Ratio -348.07% 96% 97%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.